TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Magnetic Seizure Therapy for Schizophrenia
Brief Summary: This trial attempts to evaluate the treatment efficacy of magnetic seizure therapy (MST) and its safety among schizophrenia patients. Half of the participants will be randomized to MST group, while the other half will be randomized to receive electroconvulsive therapy (ECT).


Options:
A: Arm Label: Magnetic Seizure Therapy (MST); Type: EXPERIMENTAL; Interventions: Device: MagVenture MagPro MST | Arm Label: RUL ECT; Type: ACTIVE_COMPARATOR; Interventions: Biological: RUL ECT | Intervention Type: DEVICE; Name: MagVenture MagPro MST; Assigned to Arm(s): Magnetic Seizure Therapy (MST) | Intervention Type: BIOLOGICAL; Name: RUL ECT; Assigned to Arm(s): RUL ECT
B: Arm Label: Magnetic Seizure Therapy; Type: EXPERIMENTAL; Interventions: Device: Magnetic Seizure Therapy (MagPro MST) | Intervention Type: DEVICE; Name: Magnetic Seizure Therapy (MagPro MST); Assigned to Arm(s): Magnetic Seizure Therapy
C: Arm Label: Magnetic seizure therapy; Type: EXPERIMENTAL; Interventions: Device: Magnetic seizure therapy | Arm Label: Electroconvulsive therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Electroconvulsive therapy | Intervention Type: DEVICE; Name: Magnetic seizure therapy; Assigned to Arm(s): Magnetic seizure therapy | Intervention Type: DEVICE; Name: Electroconvulsive therapy; Assigned to Arm(s): Electroconvulsive therapy
D: Arm Label: magnetic seizure therapy; Type: EXPERIMENTAL; Interventions: Device: Magpro X100 + Option, Other: treatment as usual (TAU) | Arm Label: electroconvulsive therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: ThymatronSystem Ⅳ Electroconvulsive System, Other: treatment as usual (TAU) | Intervention Type: DEVICE; Name: Magpro X100 + Option; Assigned to Arm(s): magnetic seizure therapy | Intervention Type: DEVICE; Name: ThymatronSystem Ⅳ Electroconvulsive System; Assigned to Arm(s): electroconvulsive therapy | Intervention Type: OTHER; Name: treatment as usual (TAU); Assigned to Arm(s): electroconvulsive therapy, magnetic seizure therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Veteran Engagement in Diabetes Prevention (CDA 13-267)
Brief Summary: This study will evaluate the effects of screening for type 2 diabetes mellitus (T2DM) and brief counseling about screening test results on weight and key health behaviors among Veterans with risk factors for T2DM. Study participants will be randomly assigned to one of two study groups: (1) Blood Test Group or (2) Brochure Group. Participants in the Blood Test Group will complete a blood test called hemoglobin A1c (HbA1c) which measures average blood sugar levels. Participants will receive brief counseling about the results from their primary care provider or someone authorized to speak on their behalf. Participants randomly selected for the Brochure Group will review a handout from the VA National Center for Health Promotion and Disease Prevention (NCP) on recommended screening tests and immunizations. All participants will be asked to complete a survey prior to study group assignment, immediately after a Primary Care appointment, 3 months after enrollment, and 12 months after enrollment.


Options:
A: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Structured Education | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written Information | Intervention Type: BEHAVIORAL; Name: Structured Education; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Written Information; Assigned to Arm(s): Control
B: Arm Label: Blood Test Group; Type: EXPERIMENTAL; Interventions: Behavioral: Blood Test Group Intervention | Arm Label: Brochure Group (usual care); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brochure Group Intervention | Intervention Type: BEHAVIORAL; Name: Blood Test Group Intervention; Assigned to Arm(s): Blood Test Group | Intervention Type: BEHAVIORAL; Name: Brochure Group Intervention; Assigned to Arm(s): Brochure Group (usual care)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Modified DESMOND education and ongoing support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Modified DESMOND education and ongoing support; Assigned to Arm(s): 1
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: optimised treatment | Intervention Type: PROCEDURE; Name: optimised treatment; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: eRAPID Electronic Patient Self-Reporting of Adverse-events: Patient Information and aDvice: Feasibility Pilot Study in Radiotherapy
Brief Summary: The purpose of the Electronic Patient Self-Reporting of Adverse-events: Patient Information and aDvice (eRAPID) programme is to determine whether eRAPID (an online system for patients to self-report symptoms and side effects) can enhance patient care and improve the safe delivery of cancer treatments. The investigators hypothesise that patient symptoms will be detected earlier with more timely admissions and a reduction in overall hospital contacts. It is predicted that staff will save time recording symptoms and side effects and will be able to focus attention during clinical contacts on more severe side effects. eRAPID is a cost-effective approach to supporting patient self-management and reducing hospital/General Practitioner (GP)/community contacts.

The majority of the research will be run with systemic patients. This particular part of the research is a feasibility study in radiotherapy (RT) patients to test the platform in a different patient group.


Options:
A: Arm Label: Tool + Self-management Support Program; Type: EXPERIMENTAL; Interventions: Device: Tool, Behavioral: Self-management Support Program | Arm Label: Self- management Support Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management Support Program | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tool; Assigned to Arm(s): Tool + Self-management Support Program | Intervention Type: BEHAVIORAL; Name: Self-management Support Program; Assigned to Arm(s): Self- management Support Program, Tool + Self-management Support Program
B: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: quality of life pathway | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo control | Intervention Type: BEHAVIORAL; Name: quality of life pathway; Assigned to Arm(s): intervention group | Intervention Type: OTHER; Name: placebo control; Assigned to Arm(s): control group
C: Arm Label: eRAPID intervention; Type: EXPERIMENTAL; Interventions: Device: eRAPID | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: eRAPID; Assigned to Arm(s): eRAPID intervention
D: Arm Label: IMPROVED Intervention; Type: EXPERIMENTAL; Interventions: Other: IMPROVED | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: IMPROVED; Assigned to Arm(s): IMPROVED Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of PTNS Versus Sham Efficacy in Treatment of Bladder Pain Syndrome
Brief Summary: This is a prospective, single center, double-blind, randomized, controlled trial comparing the efficacy of percutaneous tibial nerve stimulation to sham in the treatment of Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) through 12 weeks of therapy.


Options:
A: Arm Label: Post Tibial Nerve Stimulation Group (PTNS); Type: EXPERIMENTAL; Interventions: Device: NURO TM | Arm Label: Sham Group; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: NURO TM; Assigned to Arm(s): Post Tibial Nerve Stimulation Group (PTNS) | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham Group
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 1 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 2 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 3 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 4 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group 5
C: Arm Label: Usual physiotherapy treatment group; Type: ACTIVE_COMPARATOR; Interventions: Other: Routine physiotherapy control | Arm Label: Therapeutic Wand group; Type: EXPERIMENTAL; Interventions: Device: Therapeutic Wand | Intervention Type: DEVICE; Name: Therapeutic Wand; Assigned to Arm(s): Therapeutic Wand group | Intervention Type: OTHER; Name: Routine physiotherapy control; Assigned to Arm(s): Usual physiotherapy treatment group
D: Arm Label: JNJ-42160443; Type: EXPERIMENTAL; Interventions: Drug: JNJ-42160443 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: JNJ-42160443; Assigned to Arm(s): JNJ-42160443

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Implementing an Enhanced Standardized Medication Therapy Management Approach Within a Primary Care Setting
Brief Summary: The purpose of this study is to identify challenges and successes associated with implementing an enhanced medication therapy management service in primary care practice.


Options:
A: Arm Label: Traditional CERSG Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Health Worker Diabetes Education: Print media | Arm Label: Web-Based Materials Arm; Type: EXPERIMENTAL; Interventions: Behavioral: CHW Diabetes Education: tailored web site | Intervention Type: BEHAVIORAL; Name: Community Health Worker Diabetes Education: Print media; Assigned to Arm(s): Traditional CERSG Arm | Intervention Type: BEHAVIORAL; Name: CHW Diabetes Education: tailored web site; Assigned to Arm(s): Web-Based Materials Arm
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease | Intervention Type: BEHAVIORAL; Name: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease; Assigned to Arm(s): 2
C: Arm Label: Standardized care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-management education programme; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Self-Management Program | Intervention Type: BEHAVIORAL; Name: Diabetes Self-Management Program; Assigned to Arm(s): Self-management education programme
D: Arm Label: Medication therapy management; Type: EXPERIMENTAL; Interventions: Other: Medication therapy management | Intervention Type: OTHER; Name: Medication therapy management; Assigned to Arm(s): Medication therapy management

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, 52-weeks Study to Demonstrate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab Injections With 2 mL Pre-filled Syringes (300 mg) in Adult Subjects With Moderate to Severe Plaque Psoriasis
Brief Summary: The aim of the study was to demonstrate efficacy, safety and tolerability of 2 mL pre-filled syringe of 300 mg secukinumab in treatment of moderate to severe plaque psoriasis.


Options:
A: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 2 mL form; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 2 mL form | Arm Label: Secukinumab 1 mL form; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab 1 mL form | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 2 mL form; Assigned to Arm(s): Secukinumab 2 mL form | Intervention Type: DRUG; Name: Secukinumab 1 mL form; Assigned to Arm(s): Secukinumab 1 mL form
C: Arm Label: Group 1 (Guselkumab: Placebo); Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Arm Label: Group 2 (Placebo: Guselkumab); Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Group 1 (Guselkumab: Placebo), Group 2 (Placebo: Guselkumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1 (Guselkumab: Placebo), Group 2 (Placebo: Guselkumab)
D: Arm Label: 140 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 140 mg SC | Arm Label: 70 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 70 mg SC | Arm Label: 280 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 280 mg SC | Arm Label: 210 mg SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg SC | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 70 mg SC; Assigned to Arm(s): 70 mg SC | Intervention Type: DRUG; Name: 210 mg SC; Assigned to Arm(s): 210 mg SC | Intervention Type: DRUG; Name: 140 mg SC; Assigned to Arm(s): 140 mg SC | Intervention Type: DRUG; Name: 280 mg SC; Assigned to Arm(s): 280 mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast
Brief Summary: To evaluate the efficacy of etanercept in adults with moderate to severe plaque psoriasis who have failed therapy with apremilast (Otezla).


Options:
A: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab, Drug: placebo | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 140 mg brodalumab, 210 mg brodalumab, placebo
C: Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept
D: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Etanercept Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Etanercept Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab Placebo, Drug: Etanercept Placebo | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tildrakizumab Placebo, Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Tildrakizumab Placebo; Assigned to Arm(s): Etanercept 50 mg, Placebo | Intervention Type: DRUG; Name: Etanercept Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast
Brief Summary: To evaluate the efficacy of etanercept in adults with moderate to severe plaque psoriasis who have failed therapy with apremilast (Otezla).


Options:
A: Arm Label: ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab 45 mg, ustekinumab 90 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: 80 mg ixekizumab; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast
Brief Summary: To evaluate the efficacy of etanercept in adults with moderate to severe plaque psoriasis who have failed therapy with apremilast (Otezla).


Options:
A: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial
B: Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept
C: Arm Label: Group I; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group II; Type: PLACEBO_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group III; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Adalimumab | Intervention Type: DRUG; Name: Guselkumab 100 mg; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Placebo for guselkumab; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Group III | Intervention Type: DRUG; Name: Placebo for adalimumab; Assigned to Arm(s): Group I, Group II
D: Arm Label: CP 690,550 5 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 5 mg | Arm Label: CP 690,550 10 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 10 mg | Arm Label: Placebo BID+Etanercept 50 mg BIW; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept 50 mg | Arm Label: Placebo BID+Placebo BIW; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP 690,550 5 mg; Assigned to Arm(s): CP 690,550 5 mg BID+Placebo BIW | Intervention Type: DRUG; Name: CP 690,550 10 mg; Assigned to Arm(s): CP 690,550 10 mg BID+Placebo BIW | Intervention Type: BIOLOGICAL; Name: Etanercept 50 mg; Assigned to Arm(s): Placebo BID+Etanercept 50 mg BIW | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo BID+Placebo BIW

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast
Brief Summary: To evaluate the efficacy of etanercept in adults with moderate to severe plaque psoriasis who have failed therapy with apremilast (Otezla).


Options:
A: Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept
B: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Fumaric Acid Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaric Acid Esters, Drug: Ixekizumab | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Ixekizumab | Intervention Type: DRUG; Name: Fumaric Acid Esters; Assigned to Arm(s): Fumaric Acid Esters | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Fumaric Acid Esters, Ixekizumab, Methotrexate
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 1
D: Arm Label: Part 1: Guselkumab; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab | Arm Label: Part 2: Guselkumab q8w and Guselkumab q16w; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab | Arm Label: Part 2: Guselkumab q8w; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo Injection | Arm Label: Part 3: Guselkumab Withdrawal; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Part 1: Guselkumab, Part 2: Guselkumab q8w, Part 2: Guselkumab q8w and Guselkumab q16w, Part 3: Guselkumab Withdrawal | Intervention Type: DRUG; Name: Placebo Injection; Assigned to Arm(s): Part 2: Guselkumab q8w

Answer: A